多重先导编辑实现免疫抑制下可药物控制的T细胞疗法
研究开发多重先导编辑平台,将常用免疫抑制药物转化为通过特定通路耐药性在体内控制T细胞疗法的工具。在原发性人T细胞中高效编辑多个免疫失调相关致病位点并纠正SPTCL的HAVCR2驱动突变,脱靶扰动极小。在人源化小鼠模型中实现免疫抑制压力下纠正细胞的选择性体内扩增,且编辑后的抗原特异性及CAR T细胞保留效应功能。
要点
- 多重先导编辑可高效纠正T细胞中免疫失调相关致病突变且脱靶扰动小。
- 耐药性编辑使纠正细胞在免疫抑制下选择性扩增并保留对替代药物的敏感性。
- 该平台可推广至抗原特异性及CAR T细胞,实现免疫抑制下的药物可控调节。
核心结论
- 多重先导编辑是生成药物可控T细胞疗法的有前景的临床前框架,可在无法撤除免疫抑制的情况下实现选择性体内调节。
研究设计与样本
- 临床前研究,开发多重先导编辑平台,在原发性人T细胞及SPTCL患者T细胞中进行基因编辑,并在人源化小鼠模型中验证。
主要发现
- 先导编辑高效编辑原发性人T细胞中多个免疫失调相关致病位点,并纠正SPTCL患者的HAVCR2驱动突变。
- 基因组、转录、免疫表型和克隆分析显示脱靶扰动极小。
- 多重基因纠正与耐药编辑使SPTCL患者T细胞在人源化小鼠免疫抑制压力下选择性体内扩增,并保留对替代药物的敏感性。
- 先导编辑的耐药抗原特异性及CAR T细胞在药物免疫抑制下保留效应功能。
临床怎么用
- 对于需持续免疫抑制的患者(如移植受者),可考虑先导编辑赋予治疗性T细胞对特定免疫抑制药物的耐药性,以实现体内选择性扩增。
- 可设计多重编辑使纠正细胞保留对替代免疫抑制剂的敏感性,以便需要时快速体内抑制。
局限性
- 研究为临床前框架,证据来自人源化小鼠模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current cell and gene therapies lack clinically practical mechanisms to selectively promote or suppress therapeutic cells in vivo, a limitation that is particularly acute in patients requiring ongoing immunosuppression. This includes gene therapy for immune dysregulation syndromes, and antigen-specific or chimeric antigen receptor (CAR) T-cell therapy for patients requiring immunosuppression (e.g., transplant recipients), where both pathogenic and therapeutic cells may be suppressed. Here, we develop a multiplex prime-editing platform that converts commonly used immunosuppressive drugs into tools for in vivo control of T-cell therapies via defined, pathway-specific drug resistance. Focusing initially on gene therapy, prime editing efficiently edited loci of multiple pathogenic variants associated with immune dysregulation in primary human T-cells and corrected the HAVCR2 driver mutation in T-cells from multiple patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Comprehensive genomic, transcriptional, immunophenotypic, and clonal analyses demonstrated minimal off-target perturbation. Multiplexed gene correction and drug-resistance editing of T-cells from patients with SPTCL enabled selective in vivo expansion of corrected cells under immunosuppressive pressure in humanized mouse models and exhibited retained sensitivity to alternative agents permitting rapid in vivo suppression. Extending this approach, prime edited, drug-resistant antigen-specific and CAR T-cells retained effector function despite pharmacologic immunosuppression, demonstrating the generalizability of this platform to diverse cellular therapies. Together, these findings establish multiplex prime editing as a promising preclinical framework for generating drug-controllable T-cell therapies, enabling selective in vivo modulation in settings where immunosuppression cannot be withdrawn.
引用
- Bandala-Sanchez E, Petley EV, Ramsay K, et al. Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression. Blood. 2026. PMID: 42523019. doi:10.1182/blood.2026033156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。